ePoster - Epidermolysis bullosa and skin fragility

• 10 • The price of fragile skin: a scoping review on the economic burden of epidermolysis bullosa > A. Agnes GRUTTERS (Groningen) • 106 • Severe Pruritus Papules in Two Patients: Different Presentations but the Same Diagnosis > F. Fatemeh MOHAGHEGH (Isfahan) • 11 • Towards an optimal diagnostic strategy for epidermolysis bullosa (EB): the diagnostic and prognostic value of EB-diagnostics > A. Agnes GRUTTERS (Groningen) • 128 • Consensus statements for the biopsychosocial care of patients with epidermolysis bullosa South Africa: Part 2 > T. Toni Angela ROBERTS • 137 • A Case Series: Hepatic Cavernoma Complicated by Portal Hypertension in Two Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) > G. Giulia GINESI (Milan) • 139 • Development of a clinical severity score for Darier disease > V. Valentina RUFFO DI CALABRIA (Asti) • 149 • Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa > A. Artur SCHMIDTCHEN (Lund) • 150 • Non-invasive Analysis of Skin in Recessive Dystrophic Epidermolysis Bullosa Using High-Frequency Ultrasound: A First Case Report > A. Artur SCHMIDTCHEN (Lund) • 156 • NLRP7 Promoter Hypermethylation as an Epigenetic Modifier of Epidermolysis Bullosa Simplex severity > L. Lubna KHAIR (Tel Aviv) • 166 • Expert-Perceived Barriers in Epidermolysis Bullosa Clinical Trials: An International Survey > C. Christine WAGGER (Salzburg) • 177 • Apremilast in pediatric EB patient – case report > J. Jana KÝROVÁ (Brno) • 21 • Impact of losartan on disease parameters and PROS in pediatric patients with EB > M. Maria Teresa GARCIA-ROMERO (Ciudad De México) • 25 • Risk of persistent hypogammaglobulinemia in children with autoimmune bullous dermatoses treated with rituximab > S. Simon BENKIMOUN (Marseille.) • 30 • Epidermolysis bullosa simplex caused by the KRT5 Glu477Lys variant with suspected maternal mosaicism > T. Torborg STURESDOTTER HOPPE (Uppsala) • 31 • Oral budesonide in the management of dysphagia in patients with recessive dystrophic epidermolysis bullosa > C. Christine CHIAVERINI • 34 • Atypical skin phenotype linked to a double mutation in KRT1 and NECTIN4: one gene can hide another one. > C. Christine CHIAVERINI • 46 • Clitocine for Translational Read-through in Junctional Epidermolysis bullosa > R. Rui ZHANG (Freiburg) • 47 • Recessive dystrophic epidermolysis bullosa and kidney involvement > N. Nathalia BELLON (Paris) • 48 • Immune response and clinical severity are shaped by skin-adapted Staphylococcus aureus in Recessive Dystrophic Epidermolysis Bullosa patients > A. Anne JAMET • 5 • Acute phase inflammation in recessive dystrophic epidermolysis bullosa > M. Meropi KARAKIOULAKI (Freiburg) • 50 • Longitudinal Improvement in EBS Patients with De Novo KRT5 Mutations > K. Kalyani MARATHE (Cincinnati, Oh) • 54 • A Novel KRT5 Variant in a Multi-Generational Family Affected by Epidermolysis Bullosa Simplex > S. Sarah CRAWFORD • 57 • Personalized Read-Through Therapy and a New Enhancer > Y. Yan TAN (Freiburg Im Breisgau) • 76 • The Puzzling Effect of Disease Severity on Quality of Life > V. Vinzenz HUEBL • 88 • Characteristics and Treatment outcomes of Cutaneous Squamous Cell Carcinoma in Epidermolysis bullosa: A Retrospective Cohort Study. > N. Nicole MUSCOLINO (Salzburg) • 91 • Topical gene therapy in combination with birch bark extract topical gel for dystrophic epidermolysis bullosa – Bulgarian experience > K. Kossara DRENOVSKA (Sofia) • 92 • Successful Dupilumab Use in an infant with severe generalized Epidermolysis Bullosa Simplex with p.E477K mutation > N. Nathalia BELLON (Paris) • 95 • Generalized severe Epidermolysis Bullosa Simplex caused by KRT5 p.Glu477Lys: challenges encountered in this high-risk subtype > A. Agnes SCHWIEGER-BRIEL (Zurich) • 96 • Amyloidosis in Epidermolysis Bullosa: A Dual Framework for Early Risk Stratification and Misinterpretation Correction to Enhance Prevention > E. Elena BELONOGOVA DE TORREJON (London)